ImmusanT is a clinical development-stage biotechnology company focused on an innovative disease-modifying approach to induce immune tolerance in autoimmune diseases. Using our proprietary discovery platform for targeted (epitope-specific) immunotherapy, ImmusanT is developing a therapy and personalized diagnostics for celiac disease and is expanding to other autoimmune diseases including Type 1 diabetes.
We are now recruiting for clinical trials in celiac disease.
May 12, 2017
ImmusanT Announces Publication of Positive Data from Phase 1 Trials of Nexvax2 in Celiac Disease Patients
May 8, 2017
ImmusanT Reports Data on Novel Celiac Disease Diagnostic Approach
February 22, 2017
ImmusanT Announces Completion of Phase 1b Clinical Trial of Nexvax2® for the Treatment of Celiac Disease
One Kendall Square
Suite B2004
Cambridge, MA 02139
Phone: 617-299-8399